BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 27309669)

  • 21. Targeting autophagy potentiates the apoptotic effect of histone deacetylase inhibitors in t(8;21) AML cells.
    Torgersen ML; Engedal N; Bøe SO; Hokland P; Simonsen A
    Blood; 2013 Oct; 122(14):2467-76. PubMed ID: 23970379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis.
    Liu N; Wang C; Wang L; Gao L; Cheng H; Tang G; Hu X; Wang J
    Int J Mol Med; 2016 Jun; 37(6):1686-96. PubMed ID: 27082972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity.
    Heo SK; Noh EK; Yoon DJ; Jo JC; Park JH; Kim H
    PLoS One; 2014; 9(2):e98859. PubMed ID: 24918603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
    Zhao J; Xie C; Edwards H; Wang G; Taub JW; Ge Y
    Oncotarget; 2017 Jan; 8(4):6319-6329. PubMed ID: 28030834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Valproic acid for the treatment of myeloid malignancies.
    Kuendgen A; Gattermann N
    Cancer; 2007 Sep; 110(5):943-54. PubMed ID: 17647267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.
    Lai TH; Ewald B; Zecevic A; Liu C; Sulda M; Papaioannou D; Garzon R; Blachly JS; Plunkett W; Sampath D
    Clin Cancer Res; 2016 Jul; 22(14):3537-49. PubMed ID: 26858310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair.
    Maiso P; Colado E; Ocio EM; Garayoa M; Martín J; Atadja P; Pandiella A; San-Miguel JF
    Leukemia; 2009 Dec; 23(12):2265-74. PubMed ID: 19812608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.
    Qi H; Ratnam M
    Cancer Res; 2006 Jun; 66(11):5875-82. PubMed ID: 16740727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
    Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
    Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of histone deacetylase inhibitor valproic acid treatment on donor cell growth characteristics, cell cycle arrest, apoptosis, and handmade cloned bovine embryo production efficiency.
    Selokar NL; St John L; Revay T; King WA; Singla SK; Madan P
    Cell Reprogram; 2013 Dec; 15(6):531-42. PubMed ID: 24180742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy.
    Grishina O; Schmoor C; Döhner K; Hackanson B; Lubrich B; May AM; Cieslik C; Müller MJ; Lübbert M
    BMC Cancer; 2015 May; 15():430. PubMed ID: 26008690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In Vitro Effect of the Histone Deacetylase Inhibitor Valproic Acid on Viability and Apoptosis of the PLC/PRF5 Human Hepatocellular Carcinoma Cell Line.
    Sanaei M; Kavoosi F; Roustazadeh A; Shahsavani H
    Asian Pac J Cancer Prev; 2018 Sep; 19(9):2507-2510. PubMed ID: 30256044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells.
    Nie D; Huang K; Yin S; Li Y; Xie S; Ma L; Wang X; Wu Y; Xiao J
    Leuk Lymphoma; 2012 Dec; 53(12):2487-95. PubMed ID: 22642934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opposing Effects of Valproic Acid Treatment Mediated by Histone Deacetylase Inhibitor Activity in Four Transgenic
    Vent-Schmidt RYJ; Wen RH; Zong Z; Chiu CN; Tam BM; May CG; Moritz OL
    J Neurosci; 2017 Jan; 37(4):1039-1054. PubMed ID: 28490005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia.
    Wen J; Chen Y; Yang J; Dai C; Yu S; Zhong W; Liu L; He C; Zhang W; Yang T; Liu L; Hu J
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37524506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
    Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
    Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis.
    Stamatopoulos B; Meuleman N; De Bruyn C; Mineur P; Martiat P; Bron D; Lagneaux L
    Leukemia; 2009 Dec; 23(12):2281-9. PubMed ID: 19710697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid.
    Forthun RB; Sengupta T; Skjeldam HK; Lindvall JM; McCormack E; Gjertsen BT; Nilsen H
    PLoS One; 2012; 7(11):e48992. PubMed ID: 23155442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.